China biotech Rhegen has initiated a Phase II trial for its self-developed lyophilised mRNA vaccine, RH110, targeting herpes zoster. The randomised, double-blind, multicentre study will evaluate immunogenicity and safety in adults aged 40 and above. RH110, administered as a lyophilised injection, demonstrated strong safety in Phase I testing. The primary endpoints include geometric mean titres and seroconversion rates of anti-gE and anti-VZV antibodies 30 days post-vaccination.

Rhegen is a leader in mRNA technology, applying its proprietary platform across infectious diseases, oncology, and autoimmune disorders. Its subsidiary, Enobiology, offers end-to-end mRNA development solutions. The Phase II trial marks a critical step in validating RH110's potential as a differentiated preventive option for shingles, a market with significant unmet need.

PharmCube's NextBiopharm® database shows that, after this development, RH110 has become the fifth-most advanced mRNA-based VZV vaccine globally. Click here to request a free trial for NextBiopharm®.